tradingkey.logo

Fulgent Genetics Inc

FLGT
View Detailed Chart

22.490USD

+0.460+2.09%
Close 09/18, 16:00ETQuotes delayed by 15 min
688.37MMarket Cap
LossP/E TTM

Fulgent Genetics Inc

22.490

+0.460+2.09%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.09%

5 Days

+1.08%

1 Month

+4.51%

6 Months

+31.29%

Year to Date

+21.77%

1 Year

-1.83%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
32 / 72
Overall Ranking
186 / 4721
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
25.333
Target Price
+14.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Fairly Valued
The company’s latest PE is -13.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 27.21M shares, decreasing 10.32% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.16M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Ticker SymbolFLGT
CompanyFulgent Genetics Inc
CEOMr. Ming Hsieh
Websitehttps://www.fulgentgenetics.com/
KeyAI